
Why Paraguay Is the Strategic Partner Japan Can't Afford to Overlook
このページを 日本語 で読む
The world is becoming increasingly uncertain. For Japan, a resource-poor island nation that must always depend on others, strengthening ties with dependable partners is essential. Especially valuable are countries that share values like democracy and the rule of law, and that maintain a consistent diplomatic stance. One such country is Paraguay, in the heart of South America. Not only is it traditionally pro-Japan, but it is also politically stable and potentially a reliable partner in food and energy security.
Japanese media rarely report on Paraguay, despite its location in the very center of the South American continent.
Mario Toyotoshi, Paraguay's Ambassador to Japan, says, "President (Santiago) Pena often says, 'Paraguay's problem is that there are no problems.' That's why we're never in the news."
Ambassador Toyotoshi's father, Naoyuki was the founder of the Toyotoshi Group, which deals in Japanese car sales. He served as ambassador to Japan from 2009 to 2017. Born to first-generation Japanese immigrants, Mario Toyotoshi was raised in Paraguay and graduated from International Christian University (ICU) in Japan.
He briefly worked at Toyota before returning to Paraguay after one year to support the family business. Later, he spent over 30 years in Canada and elsewhere as a businessman, before being appointed ambassador at the president's request. Paraguayan Ambassador to Japan, Mario Toyotoshi (©Sankei)
Paraguay has a population of 6.86 million and a land area of 407,000 km² — about 1.1 times the size of Japan. Around 70% of the population is under 30. Diplomatic ties with Japan began in 1919, and Japanese migration started in 1936.
In 1959, following World War II, the two countries signed a migration agreement that allowed up to 85,000 Japanese immigrants. Today, there are nearly 10,000 people of Japanese descent or Japanese citizens living in Paraguay. Additionally, Japan has long been one of Paraguay's major aid donors.
After the 2011 Great East Japan Earthquake, Japanese-Paraguayan communities donated 100 tons of soybeans. These were turned into tofu and sent as relief supplies to affected areas. It's also well known that soybeans became a major export for Paraguay thanks to contributions from Japanese immigrants.
Paraguay enjoys long-term political stability. Its 2024 GDP growth rate is projected at 3.9%, compared to the Latin American average of 2.6% (before Donald Trump's tariff announcement). Its grain self-sufficiency exceeds 270%, ranking among the world's highest.
Paraguay's electricity is fully powered by hydropower, notably from the Itaipu Dam, one of the world's largest, which it cooperatively shares with Brazil. The surplus electricity that Paraguay cannot use is sold to Brazil, making electricity one of its top exports.
On diplomacy, Ambassador Toyotoshi says: "Paraguay's approach is values-based, so there's little ambiguity. We don't flip policies based on what's popular."
This unwavering stance is most evident in its relationship with Taiwan, with which it established diplomatic ties in 1957. While most countries have switched allegiance to China, only 12 nations still recognize Taiwan diplomatically, and Paraguay is the only one in South America.
Meanwhile, it's surrounded by nations with strong China ties: Brazil, Argentina, and Bolivia.
Also, Paraguay faces daily pressure from China. In December 2023, a Chinese diplomat who had received a visa to attend a UNESCO conference instead met with opposition lawmakers and publicly urged Paraguay to establish relations with China. The government cancelled his visa and deported him for engaging in activities inconsistent with his stated purpose. Such tactics are just a glimpse of Uruguay's broader resolve.
Ambassador Toyotoshi notes: "We've paid a heavy price for a values-based foreign policy."
For example, when Russia invaded Ukraine in 2022, Paraguay clearly condemned the act as a violation of a sovereign nation. In retaliation, Russia slashed beef imports from Paraguay, which had been its second-largest export market. Taiwan stepped in to buy the surplus beef and is now its largest beef importer. Still, China continues direct efforts to win over Paraguayan cattle farmers.
Paraguay's continued support for Taiwan is rooted in its Cold War history. Under dictator Alfredo Stroessner (1954–1989), Paraguay aligned with America in its anti-communist stance and received robust military and economic support. After US aid decreased in the late Kennedy era due to democratization demands, Paraguay deepened ties with Taiwan and Japan. Taiwan's President Lai Ching-te speaks at the Double Tenth Day ceremony in Taipei on October 10, 2024. (©Sankei by Yoshiaki Nishimi)
Even after democratization in 1989, it maintains its ties with Taiwan.
Ambassador Toyotoshi explains, "Paraguay values those who value us," and "After democratization, diplomacy became even more important."
Ties include Taiwan's ODA (official development assistance), EV bus plant investment, and engineer training exchanges.
In August 2023, President Lai Ching-te visited Paraguay to attend President Pena's inauguration. President Pena returned the gesture in May 2024 by attending President Lai's inauguration in Taiwan.
A new East–West corridor across South America, about 3,000 km long, is under construction. It runs roughly the distance from Hokkaido to Okinawa. Once complete, it would improve regional connectivity and reduce dependency on the Panama Canal, which is expensive and congested. Ambassador Toyotoshi estimates it could cut shipping times by three weeks. There are also plans to lay liquid natural gas pipelines along the corridor.
Japan's chance? Paraguay hopes Japan will invest in two free trade zones on the corridor's western end — Iquique and Antofagasta in northern Chile. While they are located in Chile, they are central to Paraguay's Pacific access strategy. These zones could become major logistics hubs but remain underdeveloped.
"Opportunities go to those who seize them," says the ambassador. "Paraguay is looking for investors," he adds. "Many countries are interested, but I believe Japan should recognize the strategic importance of these ports."
One major Paraguayan request is for Japan to lift the ban on Paraguayan beef. Japan prohibits imports from countries with foot-and-mouth disease, and is currently assessing Paraguay's risk.
The Ministry of Agriculture, Forestry and Fisheries says the evaluation is data-based and takes time. However, it's already been seven years since the request, and Paraguay is growing impatient. Even countries with weaker historical ties to Paraguay, like Singapore and South Korea, have shown interest in its beef.
While acknowledging the complexity of the process, Ambassador Toyotoshi says, "I'm personally very concerned. Japan is Paraguay's most important partner, yet we're falling behind other countries."
In February 2025, a tasting event for Japanese companies was held in Taipei. If the beef is processed in MAFF-certified facilities in Taiwan, Japan can legally import it. It was a creative workaround by Japanese, Taiwanese, and Paraguayan stakeholders.
While it may be important for Japan to stabilize relations with countries like China that do not share its values, it is even more urgent to deepen ties with nations that do, before it is too late.
(Read the article in Japanese .)
Author: Makiko Takita, The Sankei Shimbun
このページを 日本語 で読む
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Winnipeg Free Press
2 hours ago
- Winnipeg Free Press
Japanese court rejects damage claims against utility executives over Fukushima disaster
TOKYO (AP) — A Japanese court ruled former executives at the utility managing the tsunami-wrecked Fukushima Daiichi nuclear power plant were not accountable for the 2011 meltdown crisis and do not need to pay damages to the company. The Tokyo High Court ruling on Friday reversed a lower court decision in 2022 ordering four former executives of the Tokyo Electric Power Company Holdings to pay 13 trillion yen ($90 billion) to the company, saying they had failed to take the utmost safety precautions despite knowing the risks of a serious accident in a major tsunami. A magitude 9.0 earthquake and tsunami in March 2011 destroyed key cooling systems at the Fukushima Daiichi plant, causing its three reactors to melt down, spreading large amounts of radiation in the area and keeping tens of thousands of residents from returning home due to radioactive contamination and other safety concerns. The Tokyo District Court ruling three years ago was the only ruling that held the former TEPCO liable for the Fukushima disaster. It upheld the plaintiffs' argument that the executives had neglected to heed experts' long-term tsunami predictions and failed to take adequate tsunami precaution measures soon enough. The court said, however, the long-term tsunani prediction was not considered pressing data requiring immediate tsunami measures and it was understandable the executives had no sense of urgency from the data they had at that time, Kyodo News reported. Friday's ruling is a major disappointment for Fukushima residents and anti-nuclear activists seeking the managements' responsibility in nuclear safety. Plaintiffs and their lawyers criticized the ruling as 'unjust' and said they planned to appeal to the Supreme Court. Hiroyuki Kawai, a plaintiffs' lawyer, criticized the ruling as 'logically flawed,' saying it means nobody can be held liable for any safety negligence because tsunami and earthquake predictions are still impossible today. Monday Mornings The latest local business news and a lookahead to the coming week. A group of more than 40 TEPCO shareholders filed the lawsuit in 2012 demanding five former executives pay the company 22 trillion yen ($153 billion) in damages. The amount of the 2022 ruling against four of the executives was the highest ever ordered in a lawsuit. Japan's top court in March found two former TEPCO executives not guilty of negligence over the Fukushima meltdowns, saying a tsunami of the magnitude that hit the plant was unforeseeable. It was the only criminal trial related to the nuclear accident and the only criminal case related to the nuclear accident.


Globe and Mail
4 hours ago
- Globe and Mail
Wet Age-Related Macular Degeneration (Wet-AMD) Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Statistics, Revenue, Prevalence, and Companies by DelveInsight
Wet Age-Related Macular Degeneration Companies are Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. (Albany, USA) DelveInsight's ' Wet Age-Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034 ' report delivers an in-depth understanding of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology as well as the Wet Age-Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Wet Age-Related Macular Degeneration market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Wet Age-Related Macular Degeneration market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Wet Age-Related Macular Degeneration treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Wet Age-Related Macular Degeneration market. Key Takeaways from the Wet Age-Related Macular Degeneration Market Report In May 2025, Kodiak Sciences Inc announced results of a Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) In May 2025, NexThera Co., Ltd announced results of a Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD) In April 2025, Kodiak Sciences Inc. announced phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in the 7MM were nearly 40 million in 2023. The highest total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) were accounted by the US in 2023 (~14 million), which are expected to show a rise in the future. Among the European countries, Germany had the highest diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) with ~6 million cases in 2023. On the other hand, Spain had the lowest prevalent population (~2 million cases). Japan had nearly 8 million total diagnosed prevalent cases of Age-Related Macular Degeneration (AMD) in 2023, accounting for approximately 21% in 7MM. Based on age-specific segmentation, the people in the age group of 70-79 were affected the most by Wet Age-Related Macular Degeneration (Wet AMD) in the US, accounting for approximately 406 thousand cases in 2023. The DelveInsight analysis indicates that in Japan, there are more number of cases of people with Dry AMD than people with Wet AMD, with approximately 90% of total cases and 10% of cases in 2023. Among the European countries, Germany had the highest diagnosed prevalent cases of Wet AMD with ~595 thousand cases, followed by France, which had prevalent population of ~389 thousand in 2023. On the other hand, Spain had the lowest prevalent population (~160 thousand cases). Japan had ~840 thousand total diagnosed prevalent cases of Wet Age-Related Macular Degeneration (Wet AMD) in 2023, accounting for approximately 21% in 7MM. In 2023, in the US, the age-specific diagnosed prevalent cases of Wet AMD were highest for age group 70-79 (~407 thousand), followed by 60-69 (~393 thousand), =80 (~304 thousand), and 50-59 (~252 thousand). The increase in Wet Age-Related Macular Degeneration Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM. As per DelveInsight analysis, the Wet Age-Related Macular Degeneration Market is anticipated to witness growth at a considerable CAGR. The leading Wet Age-Related Macular Degeneration Companies such as Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. Promising Wet Age-Related Macular Degeneration Pipeline Therapies such as RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others. Wet Age-Related Macular Degeneration Epidemiology Segmentation in the 7MM The epidemiology section of Wet Age-Related Macular Degeneration offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions. Download the report to understand which factors are driving Wet Age-Related Macular Degeneration Epidemiology trends @ Wet Age-Related Macular Degeneration Marketed Drugs • BEOVU (Brolucizumab): Novartis BEOVU (Brolucizumab), developed by Novartis, is a potent anti-VEGF treatment used for Wet Age-Related Macular Degeneration (Wet-AMD). It works by inhibiting vascular endothelial growth factor, reducing abnormal blood vessel growth and fluid leakage in the retina. BEOVU offers a longer dosing interval, allowing up to 12-week dosing schedules. • EYLEA (aflibercept): Regeneron Pharmaceuticals EYLEA, developed by Regeneron, is used to treat wet age-related macular degeneration (wet-AMD), diabetic eye disease, and other retinal issues. The drug, aflibercept, is an injectable treatment that slows vision loss by blocking abnormal blood vessel growth in the eye. EYLEA works as a soluble decoy receptor, inhibiting VEGF-A and PlGF to prevent abnormal blood vessel formation. The standard dosage is 2 mg every 4 weeks for the first 3 months, then every 8 weeks. Regeneron is currently testing less frequent dosing and higher doses in ongoing phase III trials. • VABYSMO (faricimab): Roche/ Genentech, Inc. VABYSMO (faricimab) is the first bispecific antibody designed for the eye. It targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Ang-2 and VEGF-A contribute to vision loss by destabilizing blood vessels, causing new leaky blood vessels to form and increasing inflammation. By blocking both pathways involving Ang-2 and VEGF-A, VABYSMO is designed to stabilize blood vessels. Wet Age-Related Macular Degeneration Emerging Drugs • OPT-302: Opthea Limited OPT-302 (sVEGFR-3) is the first 'Trap' inhibitor of VEGF-C and VEGF-D designed specifically for the eye. OPT-302 blocks the two members of the VEGF family which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases, including wet AMD and DME. In combination with anti-VEGF-A therapies, OPT-302 completely shuts-down VEGFR-2 and VEGFR-3 activity and targets mechanisms of resistance and suboptimal clinical response to existing therapies. • KSI-501: Kodiak Sciences Inc. KSI-501 is a novel anti-VEGF biologic designed to rapidly inhibit VEGF and provide extended durability of action to reduce the burden of frequent anti-VEGF injections. Delivering potent and sustained VEGF inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes. Wet Age-Related Macular Degeneration Market Outlook Wet Age-Related Macular Degeneration (wet AMD) is a progressive eye condition characterized by the growth of abnormal blood vessels beneath the retina, which can lead to severe vision loss. Treatment aims to manage symptoms, slow disease progression, and preserve vision. The primary therapeutic approach for wet AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy. These medications, including ranibizumab (LUCENTIS), aflibercept (EYLEA), and brolucizumab (BEOVU), work by inhibiting VEGF, a protein that promotes the growth of abnormal blood vessels. Administered via intravitreal injections, these drugs reduce fluid leakage and vascular growth, stabilizing or improving vision in many patients. The Wet Age-Related Macular Degeneration (wAMD) market is driven by several key factors, including the rising prevalence of the disease due to an aging global population, increased awareness and early diagnosis, and ongoing advancements in treatment options such as anti-VEGF therapies and emerging gene therapies. Additionally, robust research pipelines, growing healthcare expenditure, and supportive government initiatives further contribute to market growth. However, the market also faces notable barriers, such as the high cost of treatment, limited accessibility in low-income regions, the need for frequent intravitreal injections, and challenges in achieving long-term efficacy and patient adherence. Moreover, competition among therapeutic alternatives and the complex nature of drug development for retinal diseases can also hinder market expansion. Wet Age-Related Macular Degeneration Drugs Uptake The drug chapter of the Wet Age-Related Macular Degeneration report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Wet Age-Related Macular Degeneration. Major Wet Age-Related Macular Degeneration Companies are Opthea Limited (ASX: OPT), Outlook Therapeutics (NASDAQ: OTLK), Kodiak Sciences (NASDAQ: KOD), Regenxbio (NASDAQ: RGNX), Dobecure (Private), Gemini Therapeutics (NASDAQ: GMTX), Huabo Biopharm (Private), Isarna Therapeutics (Private), IVERIC bio (NASDAQ: ISEE), Ribomic (TYO: 4591), Curacle (KOSDAQ: 301300), Bio-Thera Solutions (SHA: 688177), AngioLab Inc. (KOSDAQ: 251280), Alkahest (Acquired by Grifols – BME: GRF), Tyrogenex (Private), Iconic Therapeutics (Private), AiViva BioPharma (Private), Boehringer Ingelheim (Private), RemeGen (HKEX: 9995, SHA: 688331), and others Scope of the Wet Age-Related Macular Degeneration Market Report Coverage- 7MM Study Period- 2020-2034 Wet Age-Related Macular Degeneration Companies- Boehringer Ingelheim, Tyrogenex, Regenxbio, Ribomic, Outlook Therapeutics, Gemini Therapeutics, AiViva BioPharma, Opthea Limited, Iconic Therapeutics, Huabo Biopharm, Alkahest, IVERIC bio (formerly Ophthotech Corporation), Curacle, Dobecure, RemeGen, Isarna Therapeutics, Bio-Thera Solutions, Kodiak Sciences, AngioLab Inc, and others. Wet Age-Related Macular Degeneration Pipeline Therapies- RGX-314, Tarcocimab tedromer, Aflibercept, KSI-301, Eyp-1901, ALK4290, and others. Wet Age-Related Macular Degeneration Market Dynamics: Wet Age-Related Macular Degeneration Market Drivers and Barriers Wet Age-Related Macular Degeneration Market Access and Reimbursement, Unmet Needs and Future Perspectives Discover more about Wet Age-Related Macular Degeneration Drugs in development @ Wet Age-Related Macular Degeneration Clinical Trials Assessment and FDA Approvals Table of Content 1 Key Insights 2 Report Introduction 3 Wet AMD Market Overview at a Glance 4 Wet AMD Market: Future Perspective 5 Executive Summary 6 Key Events 7 Disease Background and Overview 8 Epidemiology and Patient Population 9 Patient Journey 10 Marketed Drugs 11 Emerging Drugs of Wet AMD 12 Wet AMD: Market Analysis 13 Key Opinion Leaders' Views 14 SWOT Analysis 15 Unmet Needs 16 Market Access and Reimbursement 17 Appendix 18 DelveInsight Capabilities 19 Disclaimer About DelveInsight DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:

CBC
5 hours ago
- CBC
Japanese lunar lander crashes during attempted touchdown
Social Sharing A private lunar lander from Japan crashed while attempting a touchdown Friday, the latest casualty in the commercial rush to the moon. The Tokyo-based company ispace declared the mission a failure several hours after communication was lost with the lander. Flight controllers scrambled to regain contact, but were met with only silence and said they were concluding the mission. Communications ceased less than two minutes before the spacecraft's scheduled landing on the moon with a mini-rover. Until then, the descent from lunar orbit seemed to be going well. CEO and founder Takeshi Hakamada apologized to everyone who contributed to the mission, the second lunar strikeout for ispace. Two years ago, the company's first moonshot also ended in a crash landing, giving rise to the name "Resilience" for its successor lander. "This is the second time that we were not able to land. So we really have to take it very seriously," Hakamada told reporters. He stressed that the company would press ahead with more lunar missions. Possible problem with laser system Preliminary analysis indicates the laser system for measuring the altitude did not work as planned, and the lander descended too fast, officials said. "Based on these circumstances, it is currently assumed that the lander likely performed a hard landing on the lunar surface," the company said in a written statement. Long the province of governments, the moon became a target of private outfits in 2019, with more flops than wins along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the moon faster and became the first private entity to successfully land there in March. Another U.S. company, Intuitive Machines, arrived at the moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the moon's south pole and was declared dead within hours. Resilience was targeting the top of the moon, a less treacherous place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris, or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Engineers 'did everything' possible Plans had called for the 2.3-metre Resilience to beam back pictures within hours and for the lander to lower the piggybacking rover onto the lunar surface this weekend. Made of carbon fibre-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sported a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for NASA. The rover, weighing just five kilograms, was going to stick close to the lander, going in circles at a speed of less than a few centimetres per second. It was capable of venturing up to one kilometre from the lander. Minutes before the attempted landing, Hakamada assured everyone that ispace had learned from its first failed mission. "Engineers did everything they possibly could" to ensure success this time, he said. He considered the latest moonshot "merely a steppingstone" to its bigger lander launching by 2027 with NASA involvement. Ispace, like other businesses, does not have "infinite funds" and cannot afford repeated failures, Jeremy Fix, chief engineer for the company's U.S. subsidiary, said at a conference last month. While not divulging the cost of this latest mission, company officials said it's less than the first one which exceeded $100 million US. Two other U.S. companies are aiming for moon landings by year's end: Jeff Bezos's Blue Origin and Astrobotic Technology. Astrobotic's first lunar lander missed the moon altogether in 2024 and came crashing back through Earth's atmosphere. For decades, governments competed to get to the moon. Only five countries have pulled off successful robotic lunar landings: Russia, the U.S., China, India and Japan. Of those, only the U.S. has landed people on the moon: 12 NASA astronauts from 1969 through 1972. NASA expects to send four astronauts around the moon next year. That would be followed a year or more later by the first lunar landing by a crew in more than a half-century, with SpaceX's Starship providing the lift from lunar orbit all the way down to the surface. China also has moon landing plans for its own astronauts by 2030.